Brazil · Delayed Price · Currency is BRL Novartis AG Company Description
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland, the United States, China, Germany, and internationally.
It focuses on developing products in cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and other therapeutic areas.
The company offers Entresto, an angiotensin receptor-neprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis; Kisqali, an oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Kesimpta, an anti-CD20 monoclonal antibody to treat relapsing multiple sclerosis; Promacta/Revolade for immune thrombocytopenia, thrombocytopenia, and severe aplastic anemia; Tafinlar+Mekinist, an oral combination therapy to treat various cancers; and Jakavi for myelofibrosis, polycythemia vera, and acute or chronic graft-versus-host disease (GvHD).
It also provides Tasigna and Scemblix to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for allergic asthma and nasal polyps or severe chronic rhinosinusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostate-specific membrane anti gen positive metastatic castration-resistant prostate cancer; Sandostatin SC and Sandostatin LAR for acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis for eyes; Leqvio to reduce LDL cholesterol; Lutathera, Itvisma, Fabhalta, Beovu, Coartem, and Vanrafia; and Rhapsido for chronic spontaneous urticaria.
It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Country | Switzerland |
| Founded | 1996 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,883 |
| CEO | Vasant Narasimhan |
Contact Details
Address: Lichtstrasse 35 Basel, 4056 Switzerland | |
| Phone | 41 61 324 11 11 |
| Website | novartis.com |
Stock Details
| Ticker Symbol | N1VS34 |
| Exchange | Brazil Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer |
| Harry Kirsch | Chief Financial Officer |
| Victor Bulto | President of US |
| Dr. Patrick Horber M.D. | President of International |
| Dr. Steffen Lang Ph.D. | President of Operations |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Sloan Simpson | Global Head of Investor Relations |
| Karen L. Hale | Chief Legal and Compliance Officer |
| Dr. Robert Kowalski Pharm.D. | Chief People and Organization Officer |
| Dr. Linda W. Armstrong M.D. | Global Head of Respiratory Development |